Biktarvy vs Sunlenca
A side-by-side look at two hiv medications advertised on TV. Informational only — not medical advice.
| US Biktarvy | US Sunlenca | |
|---|---|---|
| Generic name | bictegravir/emtricitabine/tenofovir alafenamide | lenacapavir |
| Drug class | Integrase Inhibitor + NRTI Combination | Capsid Inhibitor |
| Treats | HIV-1 infection | Multidrug-resistant HIV |
| Category | HIV | HIV |
| Manufacturer | Gilead Sciences | Gilead Sciences |
| Year approved | 2018 | 2022 |
| FDA warning | Black box warning | Moderate warnings |
| Est. TV ad spend | $180M | — |
| Common side effects | Worsening of hepatitis B after stopping, Headache, Diarrhea, Nausea | Injection-site reactions, Nausea, Headache, Risk of resistance if doses are missed |
Frequently asked questions
Is Biktarvy or Sunlenca better?
Neither is universally "better." Biktarvy (bictegravir/emtricitabine/tenofovir alafenamide) and Sunlenca (lenacapavir) are both used for hiv, but the right choice depends on your medical history, insurance and your doctor's guidance. This comparison is informational only.
What's the difference between Biktarvy and Sunlenca?
Biktarvy is a Integrase Inhibitor + NRTI Combination made by Gilead Sciences, while Sunlenca is a Capsid Inhibitor made by Gilead Sciences. See the table above for a side-by-side breakdown.
Which one spends more on TV ads?
Biktarvy has the larger estimated TV advertising budget of the two.